Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559786 | 0.86 | L3MBTL1 (0.46) | PDE4APDE4BPDE4CPDE4DL3MBTL1 | |
| SCHEMBL4560224 | 0.85 | PDE7A (0.35) | PDE4APDE4BPDE4CPDE4DL3MBTL1 | |
| SCHEMBL5437225 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2L3MBTL1HCAR1ALDH1A1KMT2A | |
| SCHEMBL4559992 | 0.78 | TNKS2 (0.44) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL4559996 | 0.74 | SRC (0.43) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL637358 | 0.72 | HCAR1 (0.48) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL5470187 | 0.69 | APLNR (0.47) | PDE4APDE4BPDE4CPDE4DL3MBTL1 | |
| SCHEMBL10296669 | 0.69 | PIK3CD (0.47) | PIK3CGPIK3R1 | |
| SCHEMBL733234 | 0.69 | PIK3CG (0.65) | PIK3CGALDH1A1PIK3R1PIK3CA | |
| SCHEMBL21768327 | 0.68 | HCAR1 (0.49) | HCAR1PIK3CGALDH1A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | PDE4A 846/4885PDE4B 954/4885PDE4C 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.